SAB Biotherapeutics Inc
NASDAQ:SABS
Income Statement
Earnings Waterfall
SAB Biotherapeutics Inc
Income Statement
SAB Biotherapeutics Inc
| Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||
| Interest Expense |
0
|
0
|
1
|
1
|
0
|
1
|
1
|
1
|
0
|
1
|
1
|
1
|
0
|
1
|
0
|
0
|
|
| Revenue |
61
N/A
|
73
+19%
|
79
+9%
|
83
+5%
|
24
-71%
|
13
-47%
|
6
-49%
|
4
-36%
|
2
-45%
|
3
+16%
|
3
+7%
|
2
-46%
|
1
-13%
|
0
-71%
|
0
-70%
|
0
N/A
|
|
| Operating Income | |||||||||||||||||
| Operating Expenses |
(74)
|
(93)
|
(105)
|
(116)
|
(53)
|
(42)
|
(36)
|
(31)
|
(40)
|
(45)
|
(48)
|
(53)
|
(44)
|
(42)
|
(42)
|
(43)
|
|
| Selling, General & Administrative |
(17)
|
(22)
|
(27)
|
(31)
|
(16)
|
(15)
|
(13)
|
(12)
|
(24)
|
(25)
|
(25)
|
(26)
|
(14)
|
(13)
|
(12)
|
(12)
|
|
| Research & Development |
(57)
|
(70)
|
(79)
|
(86)
|
(36)
|
(27)
|
(22)
|
(19)
|
(16)
|
(19)
|
(22)
|
(26)
|
(29)
|
(29)
|
(30)
|
(31)
|
|
| Depreciation & Amortization |
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
|
| Operating Income |
(13)
N/A
|
(20)
-49%
|
(26)
-31%
|
(34)
-28%
|
(29)
+14%
|
(29)
-2%
|
(29)
+0%
|
(27)
+8%
|
(38)
-41%
|
(42)
-10%
|
(46)
-9%
|
(52)
-13%
|
(43)
+17%
|
(42)
+2%
|
(42)
+1%
|
(43)
-3%
|
|
| Pre-Tax Income | |||||||||||||||||
| Interest Income Expense |
(0)
|
(0)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
|
| Non-Reccuring Items |
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
(4)
|
1
|
4
|
5
|
10
|
3
|
1
|
0
|
(4)
|
1
|
4
|
5
|
8
|
7
|
5
|
61
|
|
| Pre-Tax Income |
(17)
N/A
|
(19)
-11%
|
(22)
-14%
|
(28)
-31%
|
(19)
+34%
|
(27)
-45%
|
(29)
-7%
|
(27)
+7%
|
(42)
-55%
|
(40)
+6%
|
(40)
-1%
|
(46)
-13%
|
(34)
+25%
|
(34)
-1%
|
(37)
-8%
|
19
N/A
|
|
| Net Income | |||||||||||||||||
| Tax Provision |
0
|
(0)
|
0
|
0
|
(0)
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(17)
|
(19)
|
(22)
|
(28)
|
(19)
|
(27)
|
(29)
|
(27)
|
(42)
|
(40)
|
(40)
|
(46)
|
(34)
|
(34)
|
(37)
|
19
|
|
| Net Income (Common) |
(17)
N/A
|
(19)
-12%
|
(22)
-13%
|
(28)
-31%
|
(19)
+34%
|
(27)
-45%
|
(29)
-8%
|
(27)
+7%
|
(42)
-55%
|
(40)
+6%
|
(40)
-1%
|
(46)
-13%
|
(34)
+25%
|
(34)
-1%
|
(37)
-8%
|
(21)
+42%
|
|
| EPS (Diluted) |
-3.99
N/A
|
-4.43
-11%
|
-4.99
-13%
|
-6.61
-32%
|
-4.31
+35%
|
-5.37
-25%
|
-5.78
-8%
|
-5.19
+10%
|
-7.64
-47%
|
-4.31
+44%
|
-4.35
-1%
|
-4.92
-13%
|
-3.68
+25%
|
-3.7
-1%
|
-3.99
-8%
|
-0.27
+93%
|
|